GGrantIndex
← Search

Pathogen Associated Malignancies

$104,511P30FY2025CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY Nearly 20% of the worldwide burden of cancer is due to pathogens, mostly viruses and some specific bacteria. The Pathogen Associated Malignancies (PAM) Program studies pathogen associated malignancies to better prevent, diagnose, and treat these cancers. Additionally, the program aims to understand the mechanisms by which the microbiome can influence the development of cancers. The program spans basic research, treatment, and public health, and currently has 43 members across three institutions. Program members and leadership have expertise in viral and bacterial pathogenesis, infectious diseases, oncology, and public health research. Basic research focuses on HPV and genetic instability, mechanisms of Merkel Cell polyomavirus oncogenicity, KSHV latency, Helicobacter pylori’s ability to synergize with oncogenic mutations, and the effects of Fusobacterium nucleatum on the tumor microenvironment. Clinical trials include immunotherapeutic approaches to cure Merkel Cell Carcinoma. The program also has human and animal studies exploring the connections between the gut microbiota and cancer outcomes, including graft-versus-host disease, immune reconstitution after hematopoietic cell transplantation, and response to immunotherapy for cancer. The PAM program currently has $12.3M in grant funding (direct costs) of which $4.2M is from NCI. Much of the research is funded by R01s to individual investigators. Large, collaborative grants with members in both PAM and other Consortium programs include a P01 on immunology and immune therapy for Merkel cell carcinoma, a P20 on cancer health disparities, and a U54 on HPV-related cancer prevention. PAM provides many venues to stimulate intra- and inter-programmatic interactions including the yearly retreat bringing together researchers working on the microbiome with those working on virally induced cancers. There are also weekly virology meetings, monthly microbiome meetings and a wide array of sponsored seminars. Pilot grants promote new collaborations between PAM members with other investigators. The program published a total of 330 papers in the current grant cycle, of which 19% were intraprogrammatic and 43% were interprogrammatic.

View original record on NIH RePORTER →